Tetyana V. Masyuk

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

James Glockner, Eric J Bergstralh, Bernard F King, 2010, Journal of the American Society of Nephrology : JASN.

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

N. LaRusso, Bohyun Kim, J. Glockner, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The zebrafish as a model to study polycystic liver disease.

N. LaRusso, S. Ekker, G. Moulder, 2013, Zebrafish.

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.

W. Kremers, N. LaRusso, J. Glockner, 2015, Mayo Clinic proceedings.

The Role of Cilia in the Regulation of Bile Flow

N. LaRusso, Tetyana V. Masyuk, 2011, Digestive Diseases.

Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease

Marie E. Edwards, Lisa E. Vaughan, W. Kremers, 2019, Mayo Clinic proceedings. Innovations, quality & outcomes.

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

Mark R. Marten, Erinna F. Lee, Dana L. Miller, 2021, Autophagy.

MicroRNAs and Benign Biliary Tract Diseases

N. LaRusso, Tetyana V. Masyuk, S. O’Hara, 2015, Seminars in Liver Disease.

Physiology of cholangiocytes.

N. LaRusso, J. Tabibian, A. Masyuk, 2013, Comprehensive Physiology.

MicroRNAs in Cholangiopathies

N. LaRusso, J. Tabibian, Tetyana V. Masyuk, 2014, Current Pathobiology Reports.

Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis

K. Glaser, D. Thabut, V. Shah, 2011, Hepatology.

A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation.

N. LaRusso, V. Torres, P. Harris, 2007, Kidney international.

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

N. LaRusso, Bohyun Kim, J. Glockner, 2010, Journal of the American Society of Nephrology : JASN.

Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis

K. Glaser, D. Thabut, V. Shah, 2011, Hepatology.